Adrenal cortical carcinoma
Citation, DOI, disclosures and article data
At the time the article was created Saqba Farooq had no recorded disclosures.View Saqba Farooq's current disclosures
Primary adrenal cortical carcinoma (also known as adrenocortical carcinoma) is a highly malignant but rare neoplasm. It may present as a hormonally active or inactive tumor.
Although men and women are affected equally, functioning tumors are more common in females, who are also more likely to have an associated endocrine syndrome 5. The median age of presentation is around 50 years, but tumors have been found at all ages 3,4.
An additional, but smaller, incidence peak occurs in early childhood. In these cases, tumors are more likely to be functioning 5.
Incidence is low, ranging from 0.6 to 1.67 per million, per year 5.
Hormonally inactive tumors present as palpable masses, abdominal pain, or evidence of metastasis. Hormonally active tumors, representing 30-40% of all adult tumors, present with characteristic clinical manifestations 3-5:
Cushing syndrome secondary to elevated cortisol (most common)
virilisation or feminization secondary to elevated androgens
Conn syndrome secondary to hyperaldosteronism (rare)
Tumor cells can be similar to normal cortical cells, with small nuclei, pale-staining cytoplasm, and arrangement in clusters, and some cells containing large amounts of fat. In addition, the mesenchyme separating the blood vessels may be visible.
Often a suprarenal well-defined mass is seen, the appearance of which varies based on the size of the lesion. Smaller lesions are homogeneous, whereas larger lesions are heterogeneous secondary to necrosis/hemorrhage.
CT is usually the first imaging modality used.
tend to be large (>6 cm)
central areas of necrosis and hemorrhage, resulting in variable enhancement
relative contrast retention (washout <40%) on delayed contrast-enhanced CT 7
calcification is seen in up to 30% of cases
If the mass is found early, when still small, then it is difficult to distinguish from an adenoma, as aggressive features are often absent 5.
Focal extension into the renal vein, IVC, and liver are relatively common, with some series finding renal vein involvement in up to 40% of patients 5. Metastasis to regional lymph nodes, lungs, bones, and liver can occur. Liver metastases tend to be hypervascular.
MRI can be useful to determine hepatic invasion if CT is inconclusive.
A heterogeneous mass is seen that is of high signal on T2 sequences. Areas of hemorrhage may result in a variable signal intensity dependent on the age of the hemorrhage. Heterogeneous enhancement is seen with the administration of gadolinium 1,4.
Arteriography may be performed in patients who present with a large mass for which the organ of origin cannot be determined 3. Selective catheterization can identify the primary vascular supply, and thus help distinguish adrenal from renal tumors.
Treatment and prognosis
Ideally, treatment is with surgical excision, however, in many instances, the disease is advanced at the time of diagnosis, in which case chemotherapy (Mitotane) and radiation may be given for palliation.
In general, males have a poorer prognosis, largely because they are less likely to have functioning tumors, and thus present later, with more advanced disease 5.
For an adrenal mass consider other adrenal lesions 2:
known primary neoplasm
may look identical on imaging
differentiation is on histology, biochemistry, and functional status
percutaneous fine needle aspiration (FNA) of adrenal cortical carcinoma is unreliable for establishing the diagnosis 8
the most specific indications of adrenal cortical carcinoma are metastases and local invasion
- 1. Elsayes K, Mukundan G, Narra V et al. Adrenal Masses: Mr Imaging Features with Pathologic Correlation. Radiographics. 2004;24 Suppl 1(suppl_1):S73-86. doi:10.1148/rg.24si045514 - Pubmed
- 2. Mayo-Smith W, Boland G, Noto R, Lee M. State-Of-The-Art Adrenal Imaging. Radiographics. 2001;21(4):995-1012. doi:10.1148/radiographics.21.4.g01jl21995 - Pubmed
- 3. N. Reed Dunnick. Textbook of Uroradiology. (2008) ISBN: 9780781767507 - Google Books
- 4. Joseph K. T. Lee. Computed Body Tomography with MRI Correlation. (2006) ISBN: 9780781745260 - Google Books
- 5. Michael A. Blake, Giles Boland. Adrenal Imaging. (2009) ISBN: 9781934115862 - Google Books
- 6. Johnson P, Horton K, Fishman E. Adrenal Mass Imaging with Multidetector CT: Pathologic Conditions, Pearls, and Pitfalls. Radiographics. 2009;29(5):1333-51. doi:10.1148/rg.295095027 - Pubmed
- 7. Slattery J, Blake M, Kalra M et al. Adrenocortical Carcinoma: Contrast Washout Characteristics on CT. AJR Am J Roentgenol. 2006;187(1):W21-4. doi:10.2214/ajr.04.1751 - Pubmed
- 8. Weiss L, Medeiros L, Vickery A. Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma. Am J Surg Pathol. 1989;13(3):202-6. doi:10.1097/00000478-198903000-00004 - Pubmed
- 9. Else T, Kim A, Sabolch A et al. Adrenocortical Carcinoma. Endocrine Reviews. 2013;35(2):282-326. doi:10.1210/er.2013-1029 - Pubmed
- 10. Ahmed A, Thomas A, Ganeshan D et al. Adrenal Cortical Carcinoma: Pathology, Genomics, Prognosis, Imaging Features, and Mimics with Impact on Management. Abdom Radiol. 2020;45(4):945-63. doi:10.1007/s00261-019-02371-y - Pubmed
- 11. Wang F, Liu J, Zhang R et al. CT and MRI of Adrenal Gland Pathologies. Quant Imaging Med Surg. 2018;8(8):853-75. doi:10.21037/qims.2018.09.13 - Pubmed